SHENZHEN, China, June 25, 2026 -- Artivila Biopharma ("Artivila"), a clinical-stage biotech company pioneering AI-driven drug discovery, today announced the successful closing of a Series A financing of over 12.8 million USD. The round was led by Green Pine Capital Partners, with participation from Wider Link Enterprise Investment Limited and additional investors.

The capital will enable Artivila to further strengthen its R&D platforms and pipelines, accelerate clinical development and indication expansion, advance IND filings for lead candidates, and support corporate operations and international business development ahead of a planned IPO.

To date, Artivila has raised over 55 million USD in cumulative funding, reflecting strong investor confidence in its AI‑enabled platform, diversified pipeline and long-term growth potential.

Driving AI-Powered Drug Discovery Forward

Looking ahead, Artivila will continue to advance independent innovation in core technologies, deepening the integration of AI across the entire drug R&D continuum-from target discovery and molecular design to clinical development-to enhance both efficiency and precision.

The company is committed to accelerating its preclinical and clinical-stage pipelines, with the goal of bringing innovative therapies to patients with unmet medical needs as swiftly as possible. In addition, Artivila is actively expanding its global collaboration network, strengthening partnerships with multinational pharmaceutical companies and clinical research institutions. Leveraging its capital strength and industry resources, the company aims to advance its international footprint and lay a solid foundation for its future IPO, ultimately fulfilling its mission of empowering innovative drug discovery with AI for the benefit of patients worldwide.

Executive Commentary

"Artivila has successfully completed this Series A financing, backed by our robust AI platform and globally leading R&D pipeline. We are deeply grateful for the trust and support from our investors," said Dr. Zhendong Zhu, Founder and Chairman, and Dr. Deqiang Niu, Co-Founder and CEO of Artivila. "This financing will accelerate the advancement of our core pipelines and international expansion. Remaining true to our founding vision of “dedicated innovation”, we will continue to redefine the speed and precision of drug discovery with AI, and strive to deliver innovative therapeutic solutions to patients around the world."

Investor Commentary

Mr. Chong Zhang, Partner at Green Pine Capital Partners, commented: “We have long focused on the intersection of life sciences and artificial intelligence, and we firmly believe in the paradigm shift that AI brings to drug discovery. Artivila is one of the few domestic AI pharma companies that has truly integrated its AIDD platform with extensive industry experience and has already validated its approach at the clinical stage. Its founders Dr. Zhendong Zhu and Dr. Deqiang Niu bring over two decades of R&D management experience at multinational pharma and biotech companies, and their team’s strong interdisciplinary capabilities have built a comprehensive AI R&D platform covering small and large molecules, cell and gene therapy. We particularly value Artivila’s global first‑in‑class dual‑target IRAK4/1 inhibitor ARD‑885 in the autoimmune disease field, which has demonstrated excellent Phase 1 data with favorable safety profile. Its SARM1 inhibitor for neurological diseases and bispecific antibodies for cancer therapy are also among the global front‑runners. In addition, the company’s platform and pipeline value has gained international recognition, with multiple programs holding significant BD out‑licensing potential.”

About Green Pine Capital Partners

Founded in 2007 (with predecessor Green Pine Venture Capital established in 1996 as one of Shenzhen's earliest private venture capital firms), Green Pine Capital Partners was co-founded by veteran investors Li Wei and Luo Fei. The firm has demonstrated resilient performance across multiple economic cycles, with a core team possessing over 20 years of equity investment experience.

Green Pine Capital Partners focuses on early-stage and growth-stage investments, with a strategic emphasis on three core hard-tech sectors: digital technology, precision healthcare, and innovative materials. To date, the firm manages over RMB 18 billion in assets, has made more than 400 investments, and has supported over 60 portfolio companies in successful M&A or IPO exits. Select portfolio companies include SenseTime (00020.HK), BGI Genomics (300676), Kintor Pharmaceutical (09939.HK), Dynanonic (300769), MGI Tech (688114), and Orbbec (688322).

About Artivila Biopharma

Artivila Biopharma is a clinical-stage biotech company with a diversified portfolio of therapeutic programs advancing across clinical and preclinical development, focusing on improving patients' lives through an AI-powered drug development engine. Founded in late 2018 by Dr. Zhendong Zhu and Dr. Deqiang Niu with over 20 years of industry experience, Artivila integrates advanced artificial intelligence with proven R&D capabilities to accelerate the development of transformative medicines.

Leveraging its unique "AI + HI" (Artificial Intelligence + Human Intelligence) dual-driven model, Artivila combines its intelligent and modular AI R&D platform with the extensive drug development expertise of its core team to build a highly innovative and commercially promising pipeline portfolio with exceptional efficiency and cost-effectiveness.

Artivila is developing First-in-Class (FIC) and Best-in-Class (BIC) pipelines across three high-value therapeutic areas-autoimmune diseases, neurodegenerative diseases, and oncology-potential markets worth tens of billions of dollars across a broad range of indications. Artivila’s programs are among the global front-runners and the company is committed to delivering innovative medicines to patients worldwide.